Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
01 Maio 2024 - 9:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that it will host a conference call and live
webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a
corporate update and discuss the Company's financial results for
the first quarter ended March 31, 2024.
To access the conference call, investors are invited to dial +1
(800) 715-9871 (U.S. and Canada) or +1 (646) 307-1963
(International) and use the conference ID 2270373. A live audio
webcast of the call be accessed by visiting the investor relations
section of the Company’s website, www.avadel.com. A replay of the
webcast will be archived on Avadel’s website for 90 days following
the event.
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company
focused on transforming medicines to transform lives. Our approach
includes applying innovative solutions to the development of
medications that address the challenges patients face with current
treatment options. Avadel’s commercial product, LUMRYZ™, was
approved by the U.S. Food & Drug Administration (FDA) as the
first and only once-at-bedtime oxybate for the treatment of
cataplexy or excessive daytime sleepiness (EDS) in adults with
narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:Courtney MogerleyStern
Investor Relations, Inc.Courtney.Mogerley@sternir.com (212)
698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com(609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024